CBU
AUPH icon

CIBC Bancorp USA’s Aurinia Pharmaceuticals AUPH Stock Holding History

CIBC Bancorp USA’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$137K Buy
+12,414
New +$136K ﹤0.01% 1321

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CIBC Bancorp USA's AUPH Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Aurinia Pharmaceuticals (AUPH) in Q3 2025: 12,414 shares worth $137K. The stake represents ﹤0.01% of the portfolio and ranks #1321 among its holdings.

242 funds tracked by Wall St. Rank hold AUPH as of Q3 2025.

  • CIBC Bancorp USA held 12,414 shares of Aurinia Pharmaceuticals worth $137K as of Q3 2025.
  • Aurinia Pharmaceuticals was a new CIBC Bancorp USA position in Q3 2025.
  • Aurinia Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1321 holding.
  • 242 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.